首页|期刊导航|中国中药杂志|复方刺五加颗粒治疗失眠(心脾两虚证)有效性和安全性的多中心、随机、双盲双模拟、阳性药平行对照临床试验

复方刺五加颗粒治疗失眠(心脾两虚证)有效性和安全性的多中心、随机、双盲双模拟、阳性药平行对照临床试验OA

Efficacy and safety of Compound Ciwujia Granules in treating insomnia(heart-spleen deficiency syndrome):multicenter,randomized,double-blind,double-dummy,positive drug-controlled,parallel-group clinical trial

中文摘要英文摘要

为评价复方刺五加颗粒治疗失眠症(心脾两虚证)的安全性和有效性,开展了多中心、随机、双盲双模拟、阳性药平行对照临床试验.选取符合纳入、排除标准的 423 例患者,采用区组随机化方法按 1∶1 随机分配到试验组和对照组.试验组(212 例)接受复方刺五加颗粒+归脾颗粒模拟剂治疗,对照组(211 例)接受归脾颗粒+复方刺五加颗粒模拟剂治疗,2 组疗程均为 4 周,在基线与治疗后第 2、4 周进行访视.主要疗效指标包括治疗 4 周后匹兹堡睡眠质量指数(PSQI)量表评分较基线变化值、PSQI 量表评分改善率;次要疗效指标包括 PSQI 单项因子评分、睡眠日记记录变化、失眠严重指数(ISI)量表评分、镇静催眠药的使用、中医证候积分.主要疗效指标方面,治疗 4 周后试验组 PSQI 量表评分下降幅度大于对照组(P<0.000 1),PSQI 量表评分改善率优于对照组(P<0.000 1).2 组 PSQI 量表评分较基线变化值的最小二乘均数差(试验组-对照组)及95%CI 的全分析集(FAS)为-1.13[-1.63,-0.64],符合方案集(PPS)为-1.16[-1.65,-0.67],上限小于 0,认为试验组疗效优于对照组,优效性检验成立.次要疗效指标方面,治疗 4 周后试验组 PSQI 单项因子评分显著改善,ISI 量表评分和中医证候积分显著降低(P<0.05),2 组间睡眠日记记录变化和镇静催眠药的使用差异无统计学意义.试验组不良事件发生 61 例(83例次),发生率 28.77%;对照组发生 44 例(82 例次),发生率 21.05%.试验组不良反应发生 7 例(8 例次),对照组发生 8 例(12 例次),均未发生严重不良反应,实验室检查结果未提示需特别关注的异常情况.结果表明,复方刺五加颗粒服用 4 周后对失眠(心脾两虚证)疗效明确,且安全性较高.

To evaluate the safety and efficacy of Compound Ciwujia Granules in the treatment of insomnia(heart-spleen deficiency syndrome),a multicenter,randomized,double-blind,double-dummy,positive drug-controlled,parallel-group clinical trial was conducted.A total of 423 eligible patients were enrolled and randomly assigned in 1∶1 ratio to experimental group or control group using block randomization.The experimental group(n=212)received Compound Ciwujia Granules+placebo for Guipi Granules,while the control group(n=211)received Guipi Granules+placebo for Compound Ciwujia Granules.The treatment lasted for 4 weeks,with visits conducted at baseline and at weeks 2 and 4 of treatment.The primary efficacy outcomes were the change in PSQI scale scores after 4 weeks of treatment(reduction from baseline)and improvement rate of PSQI scale scores.The secondary efficacy outcomes were PSQI single factor scores,changes in sleep diary records,ISI scale scores,use of sedatives and hypnotics,and TCM syndrome scores.Regarding primary efficacy outcomes,after 4 weeks of treatment,the reduction in PSQI scale scores in the experimental group was greater than that in the control group(P<0.000 1),and the PSQI improvement rate was also superior to that of the control group(P<0.000 1).The least-squares mean difference in PSQI scale scores changes between the two groups(experimental group minus control group)and the corresponding 95%CI were-1.13[-1.63,-0.64]in FAS and-1.16[-1.65,-0.67]in PPS.As the upper limits of the confidence intervals were below 0,the efficacy of the experimental group was considered superior to that of the control group,and the superiority test was confirmed.Regarding secondary efficacy outcomes,after 4 weeks of treatment,PSQI single factor scores in the experimental group were significantly improved,and both the ISI scale scores and TCM syndrome scores were significantly reduced compared with those in the control group(P<0.05).No statistically significant differences were observed between the two groups in changes in sleep diary records the use of sedative-hypnotic drugs.In terms of safety,61 patients(83 events,28.77%)in the experimental group and 44 patients(82 events,21.05%)in the control group experienced adverse events.Adverse drug reactions occurred in 7 patients(8 events)in the experimental group and in 8 patients(12 events)in the control group.No serious adverse reactions were reported,and laboratory examinations revealed no abnormalities requiring special attention.These results indicate that Compound Ciwujia Granules administered for 4 weeks are effective and safe for the treatment of insomnia(heart-spleen deficiency syndrome).

张文静;金鑫瑶;沈莉;王国蕴;尹平;曹璐佳;郑文科

天津中医药大学 循证医学中心,天津 301617天津中医药大学 循证医学中心,天津 301617天津中医药大学 第一附属医院,天津 300193天津中医药大学 循证医学中心,天津 301617华中科技大学 公共卫生学院,湖北 武汉 430074天津中医药大学 循证医学中心,天津 301617天津中医药大学 循证医学中心,天津 301617||现代中医药海河实验室,天津 301617

失眠(心脾两虚证)复方刺五加颗粒随机对照试验中医药循证

insomnia(heart-spleen deficiency syndrome)Compound Ciwujia Granulesrandomized controlled trialevidence-based TCM

《中国中药杂志》 2026 (7)

2070-2080,11

黑龙江省"揭榜挂帅"科技攻关项目(2023ZXJ02C01)

10.19540/j.cnki.cjcmm.20251225.501

评论